Cargando…
Effect of Ivacaftor on Objective and Subjective Measures of Cough in Patients with Cystic Fibrosis
BACKGROUND AND OBJECTIVES: Cough is a major symptom in cystic fibrosis. Ivacaftor is a novel drug which targets the G551D mutation and has been demonstrated to improve lung function and weight in the long term. It also improves symptoms of extra-oesophageal reflux. We wanted to evaluate the effect o...
Autores principales: | Faruqi, Shoaib, Shiferaw, Dejene, Morice, Alyn H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Open
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299558/ https://www.ncbi.nlm.nih.gov/pubmed/28217196 http://dx.doi.org/10.2174/1874306401610010105 |
Ejemplares similares
-
Profile of tezacaftor/ivacaftor combination and its potential in the treatment of cystic fibrosis
por: Shiferaw, Dejene, et al.
Publicado: (2019) -
Chronic cough in cystic fibrosis: the effect of modulator therapy on objective 24-h cough monitoring
por: Zhang, Mengru, et al.
Publicado: (2022) -
Chronic cough associated with Crohn's disease
por: Faruqi, Shoaib, et al.
Publicado: (2010) -
Ivacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutation
por: Zeybel, Gemma L., et al.
Publicado: (2017) -
Fundoplication in chronic intractable cough
por: Faruqi, Shoaib, et al.
Publicado: (2012)